Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Lan, Lan; Han, Fei; Chen, Jianghua

doi:10.1631/jzus.b1200057

Cited by 35 publications

(31 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anyway, systematic reviews and meta-analysis of RTX use in other autoimmune disease, such as RA or Systemic Lupus Erythematosus [38,39] highlighted as main safety concerns infusion reactions and infections. Our data are in line with these observations.…”

Section: Discussionmentioning

confidence: 99%

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

et al. 2016

View full text Add to dashboard Cite

Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7-106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08-4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It has gradually been applied to other clinical immune complex diseases, such as systemic lupus erythematosus and refractory thrombocytopenic purpura, among others. In recent years, clinicians have applied rituximab to refractory renal diseases, to refractory renal diseases [3,4], although this has not been attempted in China.…”

Section: Discussionmentioning

confidence: 99%

Rituximab for Treatment of Focal Segmental Glomerulosclerosis in a Child: A Case Report

Zhou¹

2014

J Nephrol Ther

View full text Add to dashboard Cite

Objective: To study the efficacy of rituximab in children with focal sclerosing glomerulonephritis (FSGS).Case Report: Before treatment, blood biochemistry, hepatic and renal function, differential white cell counts, immunoglobulins and the complement system were assessed. Promethazine (0.5-1 mg/kg) and methylprednisolone (0.1-0.3 mg/kg) were administered intravenously 30 min and 5-10 min before the rituximab infusion. Rituximab (0.27 g) was diluted in 300 ml glucose solution and initially administered at 50 ml/hr the rate increased to 50 ml/hr every 30 min after no side effects occurred in the first hour. A second dose was given one month later. During treatment, prednisone (30mg) was taken on alternate days. Benazepril (3.3 mg) was administered every day with one chongcao capsule. Homemade ershenkang was given three times a day. Outcome: Eyelid and limb edema declined two weeks after the first application of rituximab and resolved after the second treatment. Urinary protein levels decreases, serum albumin increased, and white cell counts, hepatic function and renal function remained constant. After 3 months of followup, urine protein decreased significantly, and serum albumin (35.2 g/L) and cholesterol (5.4 mmol/L) normalized. Parameters of immune activation also reduced, and the patient remained well. Conclusion:In this case, rituximab was a safe and efficacious treatment for FSGS.

show abstract

“…Le cyclophophasmide est utilisé dans les atteintes rénales sévères. Le rituximab apparaissait prometteur dans le traitement du LES et a été évalué dans deux études prospectives randomisées qui se sont avérées négatives [24].…”

Section: Lupus éRythémateux Systémique (Les)unclassified

Indications du rituximab au cours des maladies auto-immunes

2014

La Revue de Médecine Interne

View full text Add to dashboard Cite

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Cited by 35 publications

References 38 publications

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

Rituximab for Treatment of Focal Segmental Glomerulosclerosis in a Child: A Case Report

Indications du rituximab au cours des maladies auto-immunes

Contact Info

Product

Resources

About